MMED · MiniMed Group, Inc.

Current Thesis

MiniMed Group’s standalone-growth revaluation now turns on completing Medtronic’s exchange offer and recovering the September 4 close of $23.29 before a weekly close below $20.50 breaks the structure. The operating evidence remains the September 1 earnings release: fiscal first-quarter 2027 sales of $843 million, organic growth of 15.8%, and approximately 10.5% organic growth guidance for fiscal 2027.

The material change since the September 5 dossier is the September 14 exchange-offer launch. Separation is no longer merely Medtronic’s preferred structure: the offer covers approximately 80.1% of MiniMed’s outstanding shares and is scheduled to expire on October 9, unless extended or terminated. Completion remains conditional. September 14 registration statement

The life-cycle assessment is an inference: the narrative is maturing — the September 1 growth acceleration already attracted clustered analyst revisions, while the September 14 filing moves the existing separation story into execution. The September 18 adjusted close of $21.79 remains below September 4’s $23.29 despite that progress; these observations do not establish expanding participation.

Bullish and bearish views on MiniMed Group, Inc.

The model's bull view on MiniMed Group, Inc. (MMED), in brief: Operating acceleration has reported support. The bear view: The price response remains incomplete. The September 18 adjusted close was $21.79 versus $23.29 on September 4. The new separation timetable has not restored that earlier reference close. Full-year growth trails the quarter. September 1 guidance of approximately 10.5% organic… Both cases follow in full.

Bull Case

• Operating acceleration has reported support. MiniMed’s September 1 release reported 15.8% organic growth for the quarter ended July 31, 2026, compared with 8.7% in the preceding quarter reported June 3. This supports the growth component of the thesis, although consecutive quarters do not establish durability.
• Guidance rose alongside operating improvement. On September 1, MiniMed raised fiscal 2027 organic growth guidance to approximately 10.5% and maintained approximately 16% adjusted earnings before interest, taxes, depreciation and amortization margin. Reported net income and earnings per share reached break-even in the same quarter.
• Separation now has published terms. Medtronic’s September 14 announcement established an exchange offer with a 7% discount, subject to an exchange-ratio cap. That replaces the September 1 statement of preference with an announced mechanism; it does not establish completion. Medtronic announcement

Bear Case

• The price response remains incomplete. The September 18 adjusted close was $21.79 versus $23.29 on September 4. The new separation timetable has not restored that earlier reference close.
• Full-year growth trails the quarter. September 1 guidance of approximately 10.5% organic growth compares with first-quarter growth of 15.8%; the annual outlook also includes 1.0–1.5 percentage points from an extra fiscal week. Annual guidance therefore does not validate persistence of the latest quarterly rate.
• Residual distribution remains possible. Medtronic’s September 14 announcement permits subsequent disposal through a spin-off, split-off or debt-for-equity exchange if the offer completes without full subscription. The announced split-off therefore does not eliminate uncertainty about eventual distribution. Medtronic announcement

Setup & Price Structure

The September 18 adjusted daily close was $21.79, with a three-month price increase of 53.2% and a 14-period relative strength index of 62.4. Those are measured price indicators; they do not identify the holders behind the move. A moving-average value and a participation series are unavailable, so neither distance above a rising average nor widening demand is established.

The retained research threshold is $20.50, identified in the September 5 dossier as the post-September 1 earnings shelf near August’s $20.48 high. The September 18 close remains above it. The September 4 close of $23.29 provides an observable recovery test, rather than an analyst valuation estimate.

Positioning evidence is narrower than the price gain suggests. The September 1–2 analyst reports cited in the prior dossier clustered BTIG, UBS and Bank of America targets at $28, Evercore ISI at $27, and Citigroup, Wells Fargo and Mizuho at $26. This establishes concentrated analyst attention around earnings; it does not establish retail crowding or net exchange-related hedging.

Catalyst Calendar (next 30 days)

• 2026-09-23 — Management conference appearance. MiniMed’s investor-relations calendar lists the Bank of America Global Healthcare Conference. The appearance provides a dated venue for management commentary; the listing promises no new guidance. MiniMed investor relations
• 2026-09-28 through 2026-10-02 — Diabetes research meeting. The European Association for the Study of Diabetes annual meeting takes place in Milan. Its published dates establish a category event, not a confirmed MiniMed clinical readout. Association meeting document
• 2026-10-05, 2026-10-06 and 2026-10-07 — Exchange pricing window. Medtronic’s September 14 announcement specifies these expected dates for the volume-weighted pricing calculation, conditional on no extension or termination. They determine the exchange economics. Medtronic announcement
• 2026-10-09 — Scheduled exchange-offer expiration. The September 14 filing establishes this conditional deadline. Subscription and completion disclosures resolve whether the announced separation mechanism executes. Registration statement

What Would Change Our Mind

Loss of the post-earnings shelf breaks the price thesis: a weekly close below $20.50 invalidates the case. Completion of the exchange offer followed by a weekly close above the September 4 reference close of $23.29, before that invalidation, constitutes the positive outcome being forecast.

The operating case would separately weaken if MiniMed reduced the approximately 10.5% fiscal 2027 organic growth outlook or approximately 16% adjusted margin outlook issued September 1. Cancellation of the exchange offer would remove the September 14 mechanism; an extension beyond October 9 would miss the present timetable without necessarily ending the operating thesis.

Correlation Notes

This remains a single-name separation case; the September 1 operating results and September 14 transaction terms supply its evidence. No measured return correlation with DexCom, Insulet or Tandem is established here, and the available observations are insufficient to claim a sector-driven move.

Medtronic is now a direct transaction reference because the September 14 terms use both companies’ volume-weighted prices. That establishes a contractual pricing link; it does not measure the direction or magnitude of hedging flows. Medtronic announcement